个性化新抗原疫苗3

个性化新抗原疫苗3 (Personalized Neoantigen Vaccine 3) is an investigational personalized therapeutic cancer vaccine developed by Neocura (北京新合睿恩生物医疗科技) for the treatment of solid tumors. Designed as a personalized cancer immunotherapy, the vaccine targets patient-specific tumor neoantigens, which are unique mutated proteins expressed exclusively on the patient's tumor cells. By utilizing Neocura's proprietary AI-driven platform to identify and select highly immunogenic neoantigen targets, the vaccine aims to activate and expand tumor-specific T cells (both CD4+ and CD8+), thereby inducing a precise and durable anti-tumor immune response to eliminate residual cancer cells and prevent recurrence. It is currently in the IND-enabling/clinical application phase.

Other names

Personalized Neoantigen Vaccine 3